The genus Chlamydia consists of four species, Chlamydia trachomatis, C. psittaci, C. pneumoniae, and C. pecorum (14, 18, 22) , all of which cause a broad spectrum of well-known and well-characterized human diseases. The present study concerns only C. trachomatis and C. pneumoniae. C. trachomatis causes sexually transmitted diseases including cervicitis, pelvic inflammatory disease, epididymitis, urethritis, and lymphogranuloma venereum and is associated with serious long-term sequelae such as tubal infertility and ectopic pregnancy. C. pneumoniae is a recognized cause of human respiratory infections. It has been implicated in the etiology of bronchitis, pharyngitis, sinusitis, and otitis media (17, 25) and is believed to cause about 10% of the cases of community-acquired pneumonia (12) . More recently, it has been associated with chronic heart disease, acute myocardial infarction, endocarditis, asthma, and Guillain-Barré syndrome (27) (28) (29) .
The microimmunofluorescence (MIF) test using antigens of three species (C. trachomatis, C. pneumoniae, and C. psittaci) is the recommended serological method for the diagnosis of chlamydial infection. It is very sensitive and very specific, and, until now, we have considered it the reference technique (8, 23) . However, because of the complex antigenic structure of Chlamydia species, the interpretation of the MIF test may be difficult in certain cases, especially when the titers of antibodies against two different species of Chlamydia are identical.
Western blot (immunoblot) analysis is able to detect antigenic reactivities that appear to be both genus and species specific. In the past, the only genus-specific antigen recognized for Chlamydia spp. was found to reside in the lipopolysaccharide (LPS). However, recent evidence has shown that other proteins, including the major outer membrane protein (MOMP) and 90-, 75-, 68-, 62-or 60-, 52-, and 30-kDa proteins, also have genus-reactive determinants, based on the cross-reactivity between C. trachomatis, C. pneumoniae, and C. psittaci (8, 23, 27, 31) . Thus, current serological methods are unable to distinguish between a cross-reaction due to genus specificity and a double seropositivity due to two different chlamydial infections. The purpose of this study is to show that Western blot analysis can distinguish between a cross-reaction and a double seropositivity for both C. trachomatis and C. pneumoniae.
MATERIALS AND METHODS
Serum samples. Fifty-six serum specimens obtained from women at risk of sexually transmitted disease in Brazzaville, Congo, examined previously by the MIF test for species-specific anti-Chlamydia antibodies, were analyzed by Western blot. These sera were divided into three groups according to results of the MIF.
Group 1 consisted of 28 serum samples positive for C. trachomatis-specific antibodies by MIF but negative for C. pneumoniae and C. psittaci antibodies (immunoglobulin G [IgG] titers ranging from 16 to 2,048).
Group 2 consisted of 14 serum samples positive for C. pneumoniae-specific antibodies by MIF but negative for C. trachomatis and C. psittaci antibodies (IgG anti-C. pneumoniae titers ranging from 16 to 2,048).
Group 3 consisted of 14 serum samples positive for C. trachomatis-and C. pneumoniae-specific antibodies (the IgG antibodies titers were identical) by MIF but negative for C. psittaci (IgG anti-C. trachomatis and IgG anti-C. pneumoniae titers ranging from 16 to 1,024) (two samples with a titer of 16, three with a titer of 128, four with a titer of 256, three with a titer of 512, and two with a titer of 1,024).
The MIF test was performed according to the recommendations of Grayston (16) , and IgG titers of Ն512 without concomitant elevated IgM levels were interpreted as indicative of an active infection. All select sera had IgG antiChlamydia titers ranging from 16 to 2,048 as determined by the MIF test.
C. psittaci was excluded from this analysis because of the low seroprevalence assumed for our study population. All sera had anti-C. psittaci IgG titers of Ͻ16.
Chlamydia strains. The Chlamydia strains studied included C. trachomatis serovar L2 strain LB1, C. psittaci serovar 11 strain LOTH, and C. pneumoniae IOL-207.
HL cells (Washington Research Foundation) and L929 cells (American Type Culture Collection, Rockville, Md.) were grown and maintained in Eagle's minimal essential medium (Eurobio, Les Ulis, France) supplemented with 10% heat-inactivated fetal calf serum (Eurobio les Ulis), 1% L-glutamine (200 mM in 0.85% NaCl solution) (Bio-Whittaker), and 4.4 mM sodium bicarbonate (pH 7.2). The cells were maintained at 37ЊC in 9% CO 2 in 75-cm 2 Costar flasks (Becton Dickinson, Meylan, France).
Purification of elementary bodies. After sonication and removal of cell debris, elementary bodies were pelleted by centrifugation in phosphate-buffered saline (pH 7.2) (13) and purified by centrifugation over a discontinuous 76% Renografin (Schering Laboratory, Lys-les-Lannoy, France) gradient. Purified elementary bodies were solubilized by 3 min of boiling in 0.01 M NaPO 4 H 2 -1% sodium dodecyl sulfate (SDS)-1% 2-mercaptoethanol. The suspension obtained was sedimented by centrifugation at 6,000 ϫ g for 10 min at 4ЊC. The supernatant constitutes chlamydial antigen for use in Western blots. A 0.1-ml sample of antigen was distributed in vials which were then stored at Ϫ20ЊC. Uninfected HL and L929 cells were treated in the same way for use as negative controls.
Elementary body protein concentrations were determined by the method of Lowry et al. (20) .
Test methods. Each serum sample was been tested by two techniques: the MIF method and Western blot analysis.
(i) MIF. The MIF assay of Wang and Grayston (33) as adapted by Orfila and Eb (26) was used to measure C. trachomatis, C. pneumoniae, and C. psittaci antibody titers. For test antigens in the MIF assay, 0.1 to 0.5 ml of infectious suspension of each strain was cultured on yolk sac membranes of infected 6-day-old chicken embryos. The organisms were collected in formalin-phosphate-buffered saline at a concentration of approximately 5 ϫ 10 9 organisms per ml. Antigen preparations were distributed in vials and frozen at Ϫ70ЊC.
Antichlamydial IgG antibodies from patient sera were measured by using goat fluorescein isothiocyanate-conjugated anti-human IgG (Fluoline H; BioMérieux). IgM antichlamydial antibodies from patient sera were measured by using fluorescein-conjugated goat anti-human IgM mu chain (Tago Immunologicals, Burlingame, Calif.). Sera were tested at twofold dilutions from 1:16 to 1:2,048 and were tested separately with fluorescein-conjugated antibodies to human IgM and IgG. Noninfected yolk sac membranes were used as a negative control.
(ii) Electrophoretic transfer of proteins, separation by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE), and Western blotting. The antigens used consisted of purified strains of each of the three species. C. trachomatis-and C. psittaci-infected L929 cells were harvested after 2 days of incubation, and C. pneumoniae-infected HL cells were harvested after 3 days of incubation.
Renografin-purified elementary bodies of each of the three Chlamydia species (approximately 20 g of protein) were separated by discontinuous SDS-PAGE (19), using 10% polyacrylamide gels as dictated by the resolution required. Protein bands were visualized by staining the gels with Coomassie brilliant blue R-250. Molecular masses were determined by using the following protein standards (Sigma Chemicals, Saint Quentin Fallavier, France): ␣-2-macroglobulin (180,000 kDa), ␤-galactosidase (116,000 kDa), fructose-6-phosphate kinase (84,000 kDa), pyruvate kinase (58,000 kDa), fumarase (48,500 kDa), lactic dehydrogenase (36,500 kDa), and triose phosphate isomerase (26,600 kDa).
For Western blot analysis, SDS-PAGE-separated proteins were transferred to Immobilon polyvinylidene difluoride transfer membranes (15 by 14 cm) (Millipore Corp., Bedford, Mass.) by the method of Towbin et al. (30) . The SDSdenatured proteins were transferred toward the anode in a 25 mM Tris-192 mM glycine-20% methanol (pH 8.3) buffer system for 18 h at 50-mA constant current (2103-25A-220 V; LKB Biochrom, St. Albans, England). Protein bands were subsequently visualized by staining Immobilon polyvinylidene difluoride transfer membranes with 3‰ red Ponceau S for 15 min. The dye front on the blot was marked with a pencil, and the membranes were destained three times with water for 5 min each (3).
The blots were blocked for 2 h with Eagle-inactivated fetal calf serum (Eurobio les Ulis)-1% Triton X-100 solution, dried, and cut into strips containing separated, bound, purified Chlamydia proteins. Ten microliters of human sera diluted 1:100 in Eagle-inactivated fetal calf serum-Triton X-100 was added to the strips, and incubation was carried out at 37ЊC for 60 min with end-over-end rotation. After being rinsed with phosphate-buffered saline-0.2% Tween 20 (three times, 5 min each), the strips were incubated for 60 min with goat anti-human immunoglobulin conjugated to cattle 1‰ peroxidase (ImmunotechFrance). Finally, they were washed and treated with 0.5‰ diaminobenzidinetetrahydrochloride (Sigma-Aldrich Chimie, L'Isle d'Abeau Chesnes-St. Quentin, France) in 0.1 M Tris-HCl (pH 7.6), and 0.5‰ hydrogen peroxide was then added; a brown reaction product was visible where antibody binding had occurred (15) .
The molecular weights of different bands were estimated by comparison with the protein standards referenced. The Bioprofil program, version 4.00 (19a) , was used for determination of the molecular weights of prominent bands. The bands were photographed with Koda Color Gold 400 (Kodak, Stuttgart, Germany).
RESULTS
No IgM antibody was detected. Fifty-six serum samples having IgG antibodies to C. trachomatis and to C. pneumoniae as determined by MIF were examined by Western blotting with C. trachomatis and C. pneumoniae antigens.
The results of the MIF test revealed that the staining intensity of the chlamydial protein bands did not correlate with the MIF antibody titers of the sera tested, although it was clear from the blot profiles that many proteins were specific for C. trachomatis (170, 155, 145, 120, 115, 100, 57, and 38 kDa) or for C. pneumoniae (175, 130, 110, 98, and 30 kDa), and other proteins (90-, 80-, 75-, 62-or 60-, and 55-kDa proteins and the MOMP) appeared to be shared by C. trachomatis and C. pneumoniae.
C. trachomatis or C. pneumoniae antibodies detected by MIF have been confirmed by the Western blot technique in 73.2% of the serum specimens tested: 28 serum samples having C. trachomatis antibodies as determined by MIF (group 1) had a C. trachomatis protein profile, and 13 serum samples having C. pneumoniae antibodies as determined by MIF (group 2) presented a C. pneumoniae protein profile. Of 14 serum specimens (25%; group 3) which had identical titers of C. trachomatis and C. pneumoniae antibodies by MIF, 9 showed anti-C. trachomatis protein profiles, 2 presented anti-C. pneumoniae protein profiles, and the 3 remaining serum samples had identical protein profiles for both C. trachomatis and C. pneumoniae. One serum sample (1.8%) having C. pneumoniae antibodies as determined by MIF (group 2) presented a C. trachomatis protein profile in Western blot analysis.
DISCUSSION
The analysis of the sera tested indicates that C. trachomatis is clearly distinct from C. pneumoniae. Sera that were selected as C. trachomatis or C. pneumoniae specific by MIF reacted primarily with proteins of their homologous species, thus supporting the specificity of the MIF test. However, the intensity of protein staining did not appear to correlate with antibody titer, although it is likely that antibodies detected by the different tests are directed against conformationally different antigenic determinants (Fig. 1) .
Western blot studies revealed antigenic reactivities that are shared among Chlamydia spp. (Table 1 ). All members of the genus Chlamydia have a common LPS antigen that has been shown to be identical to 2-keto-3-deoxyoctanoic acid (4, 10) . The results of our study showed that there are other genusspecific antigenic reactivities identified in the MOMP and 90-, 80-, 75-, 62-or 60-, and 55-kDa proteins of C. trachomatis and C. pneumoniae (Table 1 ). The recognition of those genusspecific antigenic reactivities is in agreement with recent reports of antigenic analysis of C. trachomatis and C. pneumoniae which have identified genus-specific reactivity of the MOMP (4, 7, 16, 21) and 77-, 75-, 68-, 60-, 39.5-, and 30-kDa proteins (6, 7, 16, 27, 31) .
Our Western blot analysis revealed a reactivity that appears to be specific for C. pneumoniae and C. trachomatis. The following proteins have been identified: 175-, 130-, 110-, 98-, and 30-kDa proteins for C. pneumoniae and 170-, 155-, 145-, 120-, 115-, 100-, 57-, and 38-kDa proteins for C. trachomatis (Table  1) . These results showed that the protein profiles of C. pneumoniae strains were easily differentiated from those of C. trachomatis strains. Such results have been found by other observers who have identified the 180-and 175-kDa (11), 98-kDa (6, 7, 11, 27) , 54-kDa (13), 42-kDa (27) , and 38-kDa (11) proteins of C. pneumoniae as species specific and the 155-kDa (5), 120-kDa (1), 100-kDa (2), and 57-kDa (2, 24) proteins of C. trachomatis as species specific.
The analysis in Table 1 showed strong antibody reactions with the 57-, 115-, 38-, 100-and 120-kDa, and 145-kDa proteins of C. trachomatis and the 30-, 98-, and 130-kDa proteins of C. pneumoniae. In comparing the two antigen-specific antibody reactions, we observed that the antigen-specific antibody response for C. pneumoniae was weaker than that for C. trachomatis. These results suggest that the C. pneumoniae proteins are less immunogenic than the C. trachomatis proteins.
Other species-specific proteins were also recognized by selected sera but at a lower frequency, i.e., the 170-and 155-kDa The 98-kDa protein of C. pneumoniae was recognized by 39.2% of serum samples having C. pneumoniae antibodies as determined by MIF (groups 2 and 3) but by only 3.5% of samples positive for C. trachomatis by MIF (group 1), although 60.7% of our C. pneumoniae-specific serum specimens did not react with the 98-kDa protein, which has been proposed as a possible diagnostic indicator of infection with this organism (6, 7) . The selection of this protein as a serodiagnostic indicator would result in a low sensitivity of detection, and our results suggest that other C. pneumoniae-specific proteins ranging from 180 to 110 kDa and 30 kDa may be of greater diagnostic value.
In our Western blot, the 42-kDa MOMP of C. trachomatis was more often reactive with C. trachomatis-positive sera as determined by MIF, with higher frequency (97.6%), while the antibody reactions with the 39-kDa MOMP were much weaker and present in only 53.5% of C. pneumoniae-positive serum samples by MIF but also in 35.7% of serum samples found positive for C. trachomatis antibodies by MIF. We observed in this investigation that the reactivity to the MOMP is a good indicator for Chlamydia infection.
The 57-kDa protein of C. trachomatis was recognized by 54.7% of serum samples positive for C. trachomatis (groups 1 and 3). This protein appeared to be specific for C. trachomatis, and it has been demonstrated that it was immunodominant in women with tubal infertility and ectopic pregnancy (32) . This study demonstrated that women who developed salpingitis had significantly lower titers of IgG antibodies to a 57-kDa antigen as determined by MIF. It suggests that the host immune response to this antigen was protective (32) .
The 75-kDa protein reacted positively with 61.9% of the serum samples tested for IgG anti-C. trachomatis antibodies (groups 1 and 3) and 52.1% of serum specimens positive for C. pneumoniae (groups 2 and 3). This protein was shown to be genus specific, but the anti-C. trachomatis antibody response was dominant. In C. trachomatis, different proteins with an approximate size of 75 kDa have been described (74-kDa [2] and 76-kDa [24] proteins), and it has been reported that the 75-kDa protein of C. trachomatis appears to be a chlamydial homolog of heat shock protein (9) , which explains the frequent and unspecific serum reactions with this protein.
Conlcusion. Analysis of antigens identified in women with C. trachomatis and C. pneumoniae infections by Western blotting has demonstrated that most subjects studied have antibodies against 170-, 155-, 145-, 120-, 115-, 100-, 57-, and 38-kDa proteins of C. trachomatis or against 175-, 130-, 110-, 98-, and 30-kDa proteins of C. pneumoniae, which contain species-specific determinants. Moreover, the 90-, 80-, 75-, 62-or 60-, and 55-kDa proteins and the MOMP, which contain genus-specific determinants, are recognized by antibodies induced by C. trachomatis and C. pneumoniae. The Western blot method may allow analysis of speciesspecific antigens of C. trachomatis or C. pneumoniae, permitting differentiation between a cross-reaction and a double specific seropositivity. In spite of these excellent results, Western blotting is a long, costly, and delicate technique. It does not adapt to current practical use, and it remains confined to research laboratories. We propose its use as a confirmation technique for antibody specificity found by the MIF test and not its use as a primary technique.
